• Home
  • Nieuws
  • Exposanten
  • Mediapartners
  • Locatie
  • Contact
  • Historie
    • LabAutomation 2023
      • Programma 2023
      • Exposanten 2023
    • LabAutomation 2022
      • Programma 2022
      • Exposanten 2022
    • LabAutomation online 2021
    • LabAutomation online kennisweek 2020
    • LabAutomation 2019
      • Programma 2019
      • Exposanten 2019
    • LabAutomation 2018
      • Presentaties en programma 2018
      • Exposanten 2018
    • LabAutomation 2017
      • Presentaties en programma 2017
      • Exposanten 2017
    • LabAutomation 2016
      • Presentaties en programma 2016
      • Exposanten 2016
    • LabAutomation 2015
      • Presentaties en programma 2015
      • Exposanten 2015
    • LabAutomation 2014
      • Presentaties en programma 2014
      • Exposanten 2014
  • Account
    • Login
  • Login
  • Zoeken

LabAutomation

LabAutomation

Validating novel biomarkers for cardiac disease

joost_leendersACS Biomarker is a biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers for cardiovascular disease, in particular heart failure. There is a high need for novel markers to improve cardiovascular risk assessment. ACS Biomarker currently develops a multi-marker test that can improve the clinical management of heart failure. In our recently opened new lab, a series of miRNAs is measured in thousands of patient samples in a high-throughput setting. Accuracy, reproducibility, and time management are key elements in this process. We therefore automated the pre-PCR step; a high-risk factor in validating miRNAs.

Joost Leenders, ACS Biomarker

Terug

Contact FHI

Brancheorganisatie Laboratorium Technologie
Telefoon: +31 (0)33 465 75 07
www.fhi.nl/laboratoriumtechnologie

Disclaimer

Privacy FHI

Cookies

Copyright © 2023 · Onderdeel van FHI ·